AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8478672 — intervention group
Group type: COMPARATOR
Intervention: Low-risk group
Number of subjects: 227
Study 8478672 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 227
Study 3739583 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ketamine
Number of subjects: 50
Study 3739583 — intervention group
Group type: COMPARATOR
Intervention: Intravenous methohexitone
Number of subjects: 50
Study 30802723 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuji apple intake (2 apples, 360 g per day for 1 week)
Number of subjects: 16
Study 27798749 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated liposomal doxorubicin (PLD) 50 mg/m2 every 28 days
Number of subjects: 210
Study 27798749 — intervention group
Group type: COMPARATOR
Intervention: Capecitabine 1250 mg/m2 twice daily for 14 days every 21 days
Number of subjects: 210
Study 27102874 — intervention group
Group type: EXPERIMENTAL
Intervention: hsTnT measurement preoperatively and at 6, 12, and 24 hours postoperatively, then every 24 hours for a maximum of 5 days
Number of subjects: 85
Study 25138661 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 g dose of the whole-grain fibre composite ingredient
Number of subjects: 90
Study 25138661 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 g dose of the whole-grain fibre composite ingredient
Number of subjects: 90
Study 25138661 — intervention group
Group type: EXPERIMENTAL
Intervention: Both doses of the whole-grain fibre composite ingredient
Number of subjects: 90
Study 25138661 — intervention group
Group type: COMPARATOR
Intervention: Maltodextrin control
Number of subjects: 90
Study 22771160 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine (oral care with a toothbrush and antiseptic gel twice a day)
Number of subjects: 96
Study 22771160 — intervention group
Group type: COMPARATOR
Intervention: Placebo (oral care with a toothbrush and non-antiseptic gel twice a day)
Number of subjects: 96
Study 22771160 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine
Number of subjects: 96
Study 18982377 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemically interesterified (CIE) stearic acid-rich fat spread
Number of subjects: 21
Study 18982377 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzymatically interesterified (EIE) stearic acid-rich fat spread
Number of subjects: 21
Study 18982377 — intervention group
Group type: COMPARATOR
Intervention: Non-interesterified (NIE) stearic acid-rich fat spread
Number of subjects: 21
Study 18982377 — intervention group
Group type: COMPARATOR
Intervention: No fat
Number of subjects: 21
Study 17599102 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocephin (Ceftriaxone) 1g intravenously at induction and 1g 12 hours later (Group 1)
Number of subjects: 89
Study 17599102 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinacef (Cefuroxime) 1.5 g intravenously at induction and 750 mg six hourly for 12 hours (Group 2)
Number of subjects: 89
Study 17599102 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprotab (ciprofloxacine) 400mg intravenously at induction and 200mg six hourly for 12 hours (Group 3)
Number of subjects: 89
Study 17599102 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-effectiveness comparison of the three antibiotics
Number of subjects: 89
Study 15603456 — intervention group
Group type: EXPERIMENTAL
Intervention: Prelingually deafened students
Number of subjects: 18
Study 15603456 — intervention group
Group type: COMPARATOR
Intervention: Hearing control group
Number of subjects: 18
Study 11752994 — intervention group
Group type: EXPERIMENTAL
Intervention: Video group
Number of subjects: 22
Study 11752994 — intervention group
Group type: COMPARATOR
Intervention: Non-video group
Number of subjects: 22
Study 10220207 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin lispro injected at 0 min before a standard lunch with a mid-afternoon snack
Number of subjects: 10
Study 10220207 — intervention group
Group type: COMPARATOR
Intervention: Humulin S (HS) injected at ‐30 min before lunch with a mid-afternoon snack
Number of subjects: 10
Study 7882475 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiopeptin (3 mg per 24 hours before PTCA followed by 6 mg per 24 hours after PTCA)
Number of subjects: 553
Study 7882475 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 553
Study 7882475 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiopeptin
Number of subjects: 553
Study 2122016 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous L-carnitine (50 mumol/kg/day for 7 days, then 100 mumol/kg/day for 7 days)
Number of subjects: 43
Study 2122016 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous L-carnitine
Number of subjects: 43
Study 363722 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose heparin
Number of subjects: 119
Study 363722 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 119
Study 31303542 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic surgical simulator (RoSS)
Number of subjects: 31
Study 31303542 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic simulator (LS)
Number of subjects: 31
Study 31303542 — intervention group
Group type: COMPARATOR
Intervention: Unpracticed modality
Number of subjects: 31
Study 31303542 — intervention group
Group type: EXPERIMENTAL
Intervention: Practiced modality (LS or RoSS)
Number of subjects: 31
Study 28865926 — intervention group
Group type: EXPERIMENTAL
Intervention: Hazard anticipation training (two classroom sessions with video clips of dangerous traffic situations)
Number of subjects: 124
Study 28865926 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training during the initial phase)
Number of subjects: 124
Study 26265063 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin (1 g) 1 h before surgery + 500 mg 8/8 h for 7 days
Number of subjects: 80
Study 26265063 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin (1 g) 1 h before surgery + placebo (identical appearance to G1) 8/8 h for 7 days
Number of subjects: 80
Study 26265063 — intervention group
Group type: COMPARATOR
Intervention: Placebo 1 h before surgery and 500 mg 8/8 h for 7 days
Number of subjects: 80
Study 23322524 — intervention group
Group type: COMPARATOR
Intervention: FEC (6 cycles)
Number of subjects: 657
Study 23322524 — intervention group
Group type: EXPERIMENTAL
Intervention: FEC-D (3 cycles of FEC followed by 3 cycles of docetaxel)
Number of subjects: 657
Study 23322524 — intervention group
Group type: COMPARATOR
Intervention: FEC
Number of subjects: 657
Study 23322524 — intervention group
Group type: EXPERIMENTAL
Intervention: FEC-D
Number of subjects: 657
Study 20848235 — intervention group
Group type: COMPARATOR
Intervention: Discontinued referrals
Number of subjects: 61931
Study 20848235 — intervention group
Group type: COMPARATOR
Intervention: Unresolved referrals
Number of subjects: 61931
Study 20848235 — intervention group
Group type: COMPARATOR
Intervention: Returned referrals to PCPs
Number of subjects: 61931
Study 20848235 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up actions
Number of subjects: 61931
Study 19530321 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg clopidogrel
Number of subjects: 95
Study 17302696 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary enalaprilat (EN), 50 mug, administered immediately after reperfusion
Number of subjects: 22
Study 17302696 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL) administered immediately after reperfusion
Number of subjects: 22
Study 14757394 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnant patients with uncomplicated falciparum malaria
Number of subjects: 20
Study 14757394 — intervention group
Group type: COMPARATOR
Intervention: Non-infected pregnant women
Number of subjects: 20
Study 11691524 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 36
Study 11691524 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol
Number of subjects: 36
Study 9330414 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 50 micrograms twice daily (b.i.d.)
Number of subjects: 122
Study 9330414 — intervention group
Group type: COMPARATOR
Intervention: Sodium cromoglycate (SCG) 20 mg four times daily (q.i.d.)
Number of subjects: 122
Study 9330414 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP)
Number of subjects: 122
Study 9330414 — intervention group
Group type: COMPARATOR
Intervention: Sodium cromoglycate (SCG)
Number of subjects: 122
Study 7953445 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterograde delivered cardioplegic solution (Group A, n = 19)
Number of subjects: 36
Study 7953445 — intervention group
Group type: COMPARATOR
Intervention: Retrograde delivered cardioplegic solution (Group B, n = 17)
Number of subjects: 36
Study 6385797 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone marrow transplantation (n=33)
Number of subjects: 111
Study 6385797 — intervention group
Group type: COMPARATOR
Intervention: Continued chemotherapy (n=46)
Number of subjects: 111
Study 31246894 — intervention group
Group type: EXPERIMENTAL
Intervention: Indapamide 1.5 mg sustained release/Amlodipine 5 mg SPC
Number of subjects: 465
Study 31246894 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine 5 mg/Valsartan 80 mg SPC
Number of subjects: 465
Study 30379942 — intervention group
Group type: EXPERIMENTAL
Intervention: Teach-Back
Number of subjects: 637
Study 30379942 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 637
Study 27050256 — intervention group
Group type: EXPERIMENTAL
Intervention: Aronia-citrus juice (ACJ) intake
Number of subjects: 16
Study 27050256 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical exercise
Number of subjects: 16
Study 27050256 — intervention group
Group type: EXPERIMENTAL
Intervention: Aronia-citrus juice (ACJ) intake and physical exercise
Number of subjects: 16
Study 25043067 — intervention group
Group type: EXPERIMENTAL
Intervention: HELIOS completed biodegradable polymer SES
Number of subjects: 287
Study 25043067 — intervention group
Group type: COMPARATOR
Intervention: PARTNER durable polymer SES
Number of subjects: 287
Study 23198712 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated telephone intervention for FOBT screening
Number of subjects: 100
Study 23198712 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 100
Study 23198712 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated telephone intervention for patients aged ≥70 years
Number of subjects: 100
Study 23198712 — intervention group
Group type: COMPARATOR
Intervention: Control group for patients aged ≥70 years
Number of subjects: 100
Study 23198712 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated telephone intervention for younger patients
Number of subjects: 100
Study 23198712 — intervention group
Group type: COMPARATOR
Intervention: Control group for younger patients
Number of subjects: 100
Study 23198712 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall cost-effectiveness
Number of subjects: 100
Study 23198712 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-effectiveness probability
Number of subjects: 100
Study 23198712 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated telephone intervention
Number of subjects: 100
Study 20353434 — intervention group
Group type: EXPERIMENTAL
Intervention: Single tablet combination of sumatriptan succinate and naproxen sodium
Number of subjects: 0
Study 20353434 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18203072 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated monitoring of blood volume, blood pressure, heart rate, and bioimpedance during hemodialysis.
Number of subjects: 19
Study 16409523 — intervention group
Group type: EXPERIMENTAL
Intervention: Avoiding blood sampling (ABS)
Number of subjects: 56
Study 16409523 — intervention group
Group type: EXPERIMENTAL
Intervention: Using the drug on prescription (PD)
Number of subjects: 56
Study 16409523 — intervention group
Group type: EXPERIMENTAL
Intervention: Over the counter (OTC)
Number of subjects: 56
Study 15245937 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacral nerve stimulation therapy
Number of subjects: 89
Study 15245937 — intervention group
Group type: COMPARATOR
Intervention: Delayed implant group (Control)
Number of subjects: 89
Study 10879416 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-40 mg/day lovastatin
Number of subjects: 6605
Study 10879416 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6605
Study 9312536 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes mellitus
Number of subjects: 143
Study 9312536 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholelithiasis
Number of subjects: 143
Study 9312536 — intervention group
Group type: COMPARATOR
Intervention: Control group (no coexisting disorders)
Number of subjects: 143
Study 9312536 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes mellitus or cholelithiasis
Number of subjects: 143
Study 1518259 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranial irradiation (mandatory in patients with leukocyte count > 70,000/mm3 and initial CNS involvement, later abandoned)
Number of subjects: 210
Study 1518259 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranial irradiation
Number of subjects: 210
Study 1518259 — intervention group
Group type: COMPARATOR
Intervention: Non-irradiated
Number of subjects: 210
Study 6472116 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet A (360 kcal, 1.5 g egg protein per kg IBW, no carbohydrate)
Number of subjects: 11
Study 6472116 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet B (340 kcal, 0.8 g egg protein per kg IBW, 0.7 g carbohydrate per kg IBW)
Number of subjects: 11
Study 31912474 — intervention group
Group type: EXPERIMENTAL
Intervention: diclofenac sodium 50 mg bid
Number of subjects: 80
Study 31912474 — intervention group
Group type: EXPERIMENTAL
Intervention: tamsulosin 0.2 mg sid
Number of subjects: 80
Study 31912474 — intervention group
Group type: EXPERIMENTAL
Intervention: combination of tamsulosin and diclofenac sodium
Number of subjects: 80
Study 31912474 — intervention group
Group type: COMPARATOR
Intervention: placebo tid
Number of subjects: 80
Study 30277539 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically predicted fasting insulin
Number of subjects: 182306
Study 30277539 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically predicted 2-h glucose
Number of subjects: 182306
Study 30277539 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically predicted BMI
Number of subjects: 182306
Study 30277539 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically predicted WHRadj BMI
Number of subjects: 182306
Study 28262473 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Dose-Rate Prostate Brachytherapy (LDR-PB) boost
Number of subjects: 398
Study 28262473 — intervention group
Group type: COMPARATOR
Intervention: Dose-Escalated External Beam Radiation Therapy (DE-EBRT) boost
Number of subjects: 398
Study 28262473 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall Survival
Number of subjects: 398
Study 25884648 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile mindfulness training plus experience sampling
Number of subjects: 140
Study 25884648 — intervention group
Group type: COMPARATOR
Intervention: Experience sampling-only (Control)
Number of subjects: 140
Study 23611930 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrofurantoin (100 mg 2 times a day for 3 days)
Number of subjects: 149
Study 23611930 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 149
Study 20724299 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided radiofrequency ablation (RFA) of the great saphenous vein (GSV); n = 90
Number of subjects: 180
Study 20724299 — intervention group
Group type: COMPARATOR
Intervention: Standard surgical treatment; n = 90
Number of subjects: 180
Study 19785725 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary abciximab administration
Number of subjects: 530
Study 19785725 — intervention group
Group type: COMPARATOR
Intervention: Intravenous abciximab administration
Number of subjects: 530
Study 16400064 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed carotenoids (beta‐carotene, lutein, and lycopene; 4 mg each)
Number of subjects: 37
Study 16400064 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta‐carotene (12 mg)
Number of subjects: 37
Study 16400064 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 14965157 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse drug event tracking calendar provided to the intervention group
Number of subjects: 74
Study 14965157 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 74
Study 11235215 — intervention group
Group type: EXPERIMENTAL
Intervention: Terazosin (TE)
Number of subjects: 38
Study 11235215 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin (TA)
Number of subjects: 38
Study 9018184 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral methylprednisolone (2 mg/kg)
Number of subjects: 49
Study 9018184 — intervention group
Group type: COMPARATOR
Intervention: Intravenous methylprednisolone (2 mg/kg)
Number of subjects: 49
Study 9018184 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (oral and i.v.)
Number of subjects: 49
Study 9018184 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients discharged home
Number of subjects: 49
Study 8475622 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy for symptomatic patients with stenosis of at least 70%
Number of subjects: 0
Study 8475622 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy for symptomatic patients with stenosis less than 30%
Number of subjects: 0
Study 8475622 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy for patients with intermediate amounts of stenosis
Number of subjects: 0
Study 8475622 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy for asymptomatic patients
Number of subjects: 0
Study 8475622 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of aspirin for asymptomatic patients
Number of subjects: 0
Study 8475622 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound as a screening procedure
Number of subjects: 0
Study 3530595 — intervention group
Group type: EXPERIMENTAL
Intervention: U-40 insulin
Number of subjects: 15
Study 3530595 — intervention group
Group type: EXPERIMENTAL
Intervention: U-100 insulin
Number of subjects: 15
Study 31903800 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 hours of speech and language telerehabilitation by videoconference per week over four consecutive weeks together with usual care
Number of subjects: 62
Study 31903800 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 62
Study 29773079 — intervention group
Group type: EXPERIMENTAL
Intervention: Linagliptin (5 mg once daily for 12 weeks)
Number of subjects: 43
Study 29773079 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for 12 weeks)
Number of subjects: 43
Study 28230008 — intervention group
Group type: EXPERIMENTAL
Intervention: TACE + argon-helium cryoablation
Number of subjects: 120
Study 28230008 — intervention group
Group type: COMPARATOR
Intervention: TACE
Number of subjects: 120
Study 24830514 — intervention group
Group type: EXPERIMENTAL
Intervention: RV 2D strain
Number of subjects: 118
Study 24830514 — intervention group
Group type: EXPERIMENTAL
Intervention: Segmental strain analysis
Number of subjects: 118
Study 24830514 — intervention group
Group type: EXPERIMENTAL
Intervention: RV 2D strain by multiplane assessment
Number of subjects: 118
Study 24830514 — intervention group
Group type: EXPERIMENTAL
Intervention: Triplane assessment of the RV
Number of subjects: 118
Study 24830514 — intervention group
Group type: EXPERIMENTAL
Intervention: 2D strain of 18 segments
Number of subjects: 118
Study 24830514 — intervention group
Group type: EXPERIMENTAL
Intervention: 2D strain of 9 segments of the RV free wall
Number of subjects: 118
Study 24830514 — intervention group
Group type: EXPERIMENTAL
Intervention: 2D strain of 3 segments in four-chamber view
Number of subjects: 118
Study 23844470 — intervention group
Group type: EXPERIMENTAL
Intervention: Male medical students
Number of subjects: 507
Study 23844470 — intervention group
Group type: COMPARATOR
Intervention: Overall multivariate test for gender
Number of subjects: 507
Study 20202800 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug Attitude Inventory (DAI) assessment
Number of subjects: 228
Study 20202800 — intervention group
Group type: EXPERIMENTAL
Intervention: PANSS-positive score
Number of subjects: 228
Study 20202800 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexual side effects
Number of subjects: 228
Study 18375253 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone added to metformin (RM)
Number of subjects: 56
Study 18375253 — intervention group
Group type: COMPARATOR
Intervention: Metformin (M)
Number of subjects: 56
Study 16470423 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (1 week postoperatively)
Number of subjects: 142
Study 16470423 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (2 weeks postoperatively)
Number of subjects: 142
Study 16470423 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (combined treatment)
Number of subjects: 142
Study 16470423 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control group)
Number of subjects: 142
Study 12351281 — intervention group
Group type: EXPERIMENTAL
Intervention: mexiletine 600 mg/d
Number of subjects: 75
Study 12351281 — intervention group
Group type: EXPERIMENTAL
Intervention: gabapentin 1200 mg/d
Number of subjects: 75
Study 12351281 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 75
Study 9833192 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipenem/Cilastatin
Number of subjects: 154
Study 9833192 — intervention group
Group type: COMPARATOR
Intervention: Alternative regimens
Number of subjects: 154
Study 7865998 — intervention group
Group type: EXPERIMENTAL
Intervention: Danyihewei granule (DYHW)
Number of subjects: 51
Study 7865998 — intervention group
Group type: EXPERIMENTAL
Intervention: Rongshisan (RSS)
Number of subjects: 51
Study 7865998 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 51
Study 2702922 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening tests for depressive disorders
Number of subjects: 0
Study 2702922 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening tests for anxiety disorders
Number of subjects: 0
Study 2702922 — intervention group
Group type: COMPARATOR
Intervention: Non-depressed comparison group (including subjects with remitted disorder)
Number of subjects: 0